DK0613683T4 - Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation - Google Patents

Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation

Info

Publication number
DK0613683T4
DK0613683T4 DK94101461T DK94101461T DK0613683T4 DK 0613683 T4 DK0613683 T4 DK 0613683T4 DK 94101461 T DK94101461 T DK 94101461T DK 94101461 T DK94101461 T DK 94101461T DK 0613683 T4 DK0613683 T4 DK 0613683T4
Authority
DK
Denmark
Prior art keywords
preparation
erythropoietin
inhalation
pulmonary administration
epo
Prior art date
Application number
DK94101461T
Other languages
Danish (da)
English (en)
Other versions
DK0613683T3 (da
Inventor
Colin G Pitt
Robert M Platz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21760356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0613683(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DK0613683T3 publication Critical patent/DK0613683T3/da
Application granted granted Critical
Publication of DK0613683T4 publication Critical patent/DK0613683T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94101461T 1993-02-04 1994-02-02 Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation DK0613683T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/013,514 US5354934A (en) 1993-02-04 1993-02-04 Pulmonary administration of erythropoietin

Publications (2)

Publication Number Publication Date
DK0613683T3 DK0613683T3 (da) 2000-04-03
DK0613683T4 true DK0613683T4 (da) 2003-07-14

Family

ID=21760356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94101461T DK0613683T4 (da) 1993-02-04 1994-02-02 Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation

Country Status (14)

Country Link
US (1) US5354934A (fr)
EP (1) EP0613683B2 (fr)
JP (1) JP4338214B2 (fr)
AT (1) ATE187061T1 (fr)
AU (1) AU677378B2 (fr)
CA (1) CA2155334C (fr)
DE (1) DE69421835T3 (fr)
DK (1) DK0613683T4 (fr)
ES (1) ES2139678T5 (fr)
GR (1) GR3032374T3 (fr)
HK (1) HK1009239A1 (fr)
IL (1) IL108528A (fr)
WO (1) WO1994017784A1 (fr)
ZA (1) ZA94737B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
AU689217B2 (en) 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DE69534318T2 (de) 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
CA2216443A1 (fr) * 1995-03-31 1996-10-03 Aradigm Corporation Administration intrapulmonaire d'un medicament hematopoietique
DE69634246T2 (de) * 1995-04-14 2006-01-12 Nektar Therapeutics, San Carlos Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
ES2303338T3 (es) 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
AU724503B2 (en) * 1996-04-29 2000-09-21 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP1019023B1 (fr) 1997-09-29 2003-05-07 Inhale Therapeutic Systems, Inc. Preparations stabilisees pour nebuliseurs
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
CA2326384A1 (fr) 1998-04-22 1999-10-28 Cornell Research Foundation, Inc. Gene de l'erithropoietine canine et proteine recombinee
CN1367701A (zh) * 1999-05-11 2002-09-04 奥索-麦克尼尔药物公司 红细胞生成素给药的药代动力学和药效模型
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
JP2003514524A (ja) 1999-11-18 2003-04-22 コルバス・インターナショナル・インコーポレイテッド エントセリアーゼをコードしている核酸、エンドセリアーゼおよびその使用
BR0016879A (pt) * 1999-12-30 2002-12-03 Chiron Corp Métodos para transferência de interleucina-2 por via pulmonar
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ.ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
ATE420630T1 (de) * 2000-11-29 2009-01-15 Itoham Foods Inc Pulverzubereitungen und verfahren zu ihrer herstellung
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
RU2317086C2 (ru) * 2001-02-02 2008-02-20 Орто-Макнейл Фармасьютикал, Инк. Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
EP1383884A4 (fr) 2001-03-22 2004-12-15 Dendreon Corp Molecules d'acide nucleique codant la serine protease cvsp14, polypeptides codes et procedes
ATE333290T1 (de) * 2001-05-21 2006-08-15 Injet Digital Aerosols Ltd Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1458360B1 (fr) 2001-12-19 2011-05-11 Novartis AG Administration pulmonaire d'aminoglycosides
WO2003055526A2 (fr) * 2001-12-21 2003-07-10 Maxygen Aps Conjugues d'erythropoietine
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
CA2484676A1 (fr) 2002-05-03 2003-11-13 Sequenom, Inc. Muteines de proteines d'ancrage de kinase, leurs peptides, et procedes associes
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
AU2003275077B2 (en) 2002-09-18 2010-02-04 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
EP1852441B1 (fr) 2002-09-24 2012-03-28 The Burnham Institute Agents qui modulent l'activité du récepteur EPH
EP1575562B1 (fr) * 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Particles polymeriques flottantes liberant des agents therapeutiques
US20040132645A1 (en) * 2003-01-03 2004-07-08 Knox Susan J. Methods for modulating effects of radiation in a subject
EP2397128A1 (fr) 2003-02-14 2011-12-21 Children's Hospital & Research Center at Oakland Utilisation de l'arginine optionnellement associée au magnésium pour le traitement de l'anémie falciforme et/ou de l'hypertension pulmonaire
AU2004229465B2 (en) * 2003-04-09 2010-04-29 The United States Of America Department Of Veterans Affairs Compositions and methods related to production of erythropoietin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
WO2006089228A2 (fr) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugues d'une fraction d'epo et d'un polymere
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
TW200810773A (en) * 2006-04-19 2008-03-01 Alba Therapeutics Corp Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
EP2425820B1 (fr) 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Procédé pour l'administration thérapeutique de DHE pour soulager rapidement la migraine tout en diminuant son profil d'effets secondaires
LT3494986T (lt) 2008-08-14 2020-07-10 Acceleron Pharma Inc. Gdf gaudyklės
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
BR122019023166B1 (pt) * 2011-10-17 2021-02-23 Acceleron Pharma, Inc Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose
ES2641325T3 (es) 2012-01-26 2017-11-08 Christopher J. Soares Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US10105410B2 (en) 2014-03-10 2018-10-23 Rambam Med-Tech Ltd. Heparanase inhibitory peptides and use thereof for treating clinical pathologies
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
IL265099B1 (en) 2016-09-02 2024-05-01 Christopher J Soares Medicinal compositions containing an effective amount of a calcitonin gene-related peptide (CGRP) receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of glaucoma
BR112020001367A2 (pt) 2017-07-26 2020-08-11 Janssen Pharmaceutica N.V. métodos de proteção da integridade vascular induzida por terapia de radiação direcionada
US11273203B2 (en) 2019-01-25 2022-03-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
CA3127455A1 (fr) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methodes d'attenuation d'une lesion hepatique et de promotion d'une hypertrophie hepatique, de regeneration du foie et de prise de greffe de cellules hepatiques conjointement avec des traitements par radiotherapie et/ou radiomimetiques
WO2020154637A1 (fr) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
JP2022526367A (ja) 2019-03-29 2022-05-24 ピエリス ファーマシューティカルズ ゲーエムベーハー リポカリンムテインの吸入投与
CN114502191A (zh) 2019-08-01 2022-05-13 Acm生物实验室私人有限公司 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
EP4138899A2 (fr) 2020-04-24 2023-03-01 ACM Biolabs Pte Ltd Vaccin contre les coronavirus pathogènes humains
CA3193643A1 (fr) 2020-12-11 2022-06-16 Madhavan Nallani Modulation de la reponse immunitaire th1/th2 par administration de deux populations de polymersomes presentant un antigene associe et un adjuvant associe
AU2022216818A1 (en) 2021-02-02 2023-07-27 Acm Biolabs Pte Ltd Sole use of polymersome associated adjuvant for stimulating an immune response
WO2022214649A1 (fr) 2021-04-08 2022-10-13 Pieris Pharmaceuticals Gmbh Nouvelles mutéines de lipocaline spécifiques au facteur de croissance des tissus conjonctifs (ctgf)
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production
WO2023168426A1 (fr) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions et cellules contenant des mélanges de protéines de fusion oligo-trap (ofps) et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (de) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultraschall-Nebelerzeugungsgeraet
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
JP2851627B2 (ja) * 1987-10-15 1999-01-27 シンテックス(ユー・エス・エイ)インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5394866A (en) 1991-03-05 1995-03-07 Aradigm Corporation Automatic aerosol medication delivery system and methods
CA2082951C (fr) * 1991-03-15 1999-12-21 Robert M. Platz Administration au niveau pulmonaire du facteur stimulant la proliferation des granulocytes
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
CA2127877A1 (fr) 1992-01-21 1993-07-22 Robert M. Platz Procede ameliore pour la preparation de medicaments polypeptidiques microfins
KR100208979B1 (ko) 1992-06-12 1999-07-15 야스이 쇼사꾸 기도내 투여용 제제

Also Published As

Publication number Publication date
US5354934A (en) 1994-10-11
ES2139678T3 (es) 2000-02-16
EP0613683B2 (fr) 2003-06-04
IL108528A (en) 1999-05-09
WO1994017784A1 (fr) 1994-08-18
HK1009239A1 (en) 1999-05-28
CA2155334C (fr) 2006-08-15
DE69421835T3 (de) 2003-12-24
ZA94737B (en) 1994-09-29
ES2139678T5 (es) 2003-12-01
JPH08507753A (ja) 1996-08-20
DE69421835T2 (de) 2000-05-18
DE69421835D1 (de) 2000-01-05
DK0613683T3 (da) 2000-04-03
AU677378B2 (en) 1997-04-24
AU6098794A (en) 1994-08-29
EP0613683B1 (fr) 1999-12-01
EP0613683A1 (fr) 1994-09-07
JP4338214B2 (ja) 2009-10-07
IL108528A0 (en) 1994-05-30
GR3032374T3 (en) 2000-04-27
CA2155334A1 (fr) 1994-08-18
ATE187061T1 (de) 1999-12-15

Similar Documents

Publication Publication Date Title
DK0613683T3 (da) Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation
FR2651677B1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
ATE77557T1 (de) Zusammensetzung zur erhoehung der intrazell-atpspiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
IL90435A (en) 4-(quinoline-2-yl-methoxy) phenylacetic acid derivatives, their preparation and pharmaceutical compositions containing them
ATE2616T1 (de) 1-aryl-2-acylamido-3-fluor-1-propanole, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DK0416950T3 (da) Medikamenter
WO1998009599A3 (fr) Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
PT89802A (pt) Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas
NO924578D0 (no) Ny taurinbasert farmasoeytisk blanding for administrering ved inhalasjon
DK144885D0 (da) Substituerede 4-hydroxybenzopyraner eller farmaceutisk acceptable additionssalte deraf, deres fremstilling og anvendelse som laegemidler
DK624186D0 (da) 6h-isoxazolo(5,4-d)pyrazolo(3,4-6)pyridiner eller farmaceutisk acceptable syreadditionssalte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter til fremstillingen
SE8503771L (sv) Nya farmaceutiska preparat
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
DE69121058D1 (de) Salze von Glykosaminoglykanen mit Aminosäureester, ihre Herstellung sowie sie enthaltende pharmazeutische Zusammensetzungen
JPS6456622A (en) Percutaneous absorbefacient base composition
DE3853958D1 (de) Substituierte Pyridin-Verbindungen, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DK568584A (da) Azabicyclo(3,3,1)nonan-9-oner eller stereoisomere eller farmaceutiskacceptable syreadditionssalte deraf, deres fremstilling og anvendelse samt mellemprodukter til fremstillingen
ATE4808T1 (de) Piperidinderivate von 3-hydroxy-thiophen-2carbons[ureestern,ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
St Jean et al. Does absorption mediate hypnotic time perception?
DE3579074D1 (de) Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
IT1203976B (it) Derivati dell'ergolene, composizioni farmaceutiche che li contengono e procedimento per la preparazione dei medesimi
IT8422646A0 (it) Contengono. composti derivati dell'acido beta-ossimino-propionico adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li
DE3672635D1 (de) Esterderivate von 2,2-dimethyl-3-ethenylcyclopropancarbonsaeure, ihre herstellung, ihre verwendung als parasitizide und sie enthaltende zusammensetzungen.
LaRue USX Sets Major Divestitures: American Bridge Sold to Its President, Rowley
ATE7385T1 (de) Derivate von 2-hydroxyoxalsaeureanilid und deren salze, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.